Drospirenone/Ethinylestradiol 3mg/20µg (24/4 Day Regimen)

  title={Drospirenone/Ethinylestradiol 3mg/20µg (24/4 Day Regimen)},
  author={Caroline Fenton and Keri David. Wellington and Marit D. Moen and Dean M. Robinson},
SummaryAbstractDrospirenone 3mg with ethinylestradiol 20µg (Yaz®) is a low-dose combined oral contraceptive (COC) administered in a regimen of 24 days of active tablets followed by a short hormone-free interval (4 days; 24/4 regimen). Drospirenone, unlike other synthetic progestogens used in COCs, is a 17α-spirolactone derivative and a 17α-spironolactone analogue with antimineralocorticoid and antiandrogenic properties. Drospirenone/ethinylestradiol 3mg/20µg (24/4) is approved in the US for the… 

A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinilestradiol 3 mg/20 mcg

From the preliminary experience, Drospirenone/Ethinylestradiol 3 mg/20 mcg seems to be promising in endometriosis management, both in cyclic and continuous regimen for endometRIosis management.

Beyaz®: An Oral Contraceptive Fortified with Folate

The folate-containing pill may aid in reducing the risk of neural tube defects in a pregnancy conceived during use or shortly after the discontinuation of the product.

Nomegestrol Acetate/Estradiol

Overall, compared with drospirenone/ethinylestradiol, nomegestrol acetate/ESTradiol appeared to be associated with less favourable acne-related outcomes, and shorter, lighter or absent periods.

Nomegestrol acetate/estradiol: a guide to its use in oral contraception

Nomegestrol acetate/estradiol (Zoely™) is the first monophasic combined oral contraceptive to contain estradiol and was at least as effective (in terms of the Pearl Index) as drospirenone/ethinylESTradiol.

Conventional vs. extended-cycle oral contraceptives on the quality of sexual life: comparison between two regimens containing 3 mg drospirenone and 20 µg ethinyl estradiol.

Women could use OCs in a subjective flexible modality and the extended-cycle OC might produce positive effects on the quality of sexual life, enforcing the concept of tailoring an OC to a woman.

Contraceptive use in acne.



Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol

  • P. RosenbaumW. Schmidt R. Heithecker
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2000
The combination of 3 mg drospirenone/30 μg ethinylestradiol (Yasmin ®, Schering AG) reliably inhibits ovulation, with a low frequency of follicular maturation, and provides a reasonable safety margin.

Added benefits of drospirenone for compliance

  • J. Foidart
  • Medicine, Biology
    Climacteric : the journal of the International Menopause Society
  • 2005
Significant improvements were observed in quality of life during treatment with 1 mg 17β-estradiol/2 mg drospirenone, which also resulted in higher mean scores than estradiol alone, and that the effect on body weight is dependent on the dose of drospirnone, and this is due to droSpirenone's antimineralocorticoid activity.

Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder

A 24/4 regimen of drospirenone 3 mg and ethinyl estradiol 20 &mgr;g improves symptoms associated with premenstrual dysphoric disorder.


Data from several 1- to 2-year studies show that EE/DRSP is an effective oral contraceptive, with Pearl index values similar to those of established low-dose CCs, and appears to be a useful treatment option for women desiring oral contraception.

Drospirenone: a Novel Progestogen with Antimineralocorticoid and Antiandrogenic Activity

Drospirenone exerts potent progestogenic and antigonadotropic activity which was studied in various animal species and efficiently promotes the maintenance of pregnancy in ovariectomized rats, inhibits ovulation in rats and mice and stimulates endometrial transformation in the rabbit.

Safety of a New Oral Contraceptive Containing Drospirenone

Overall, the safety data with EE/DRSP and other OCs indicate that these products have no negative impact on the risk of VTE (and other adverse events) in women who receive OCs for contraception.